PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals

Phathom Pharmaceuticals told investors on April 30, 2026 that it was "maintaining" its FY 2026 revenue guidance of $320 million to $345 million. Weeks later, the Company cut that outlook to $310 million to $325 million, and PHAT shares fell. NEW YORK, July 31, 2026 /PRNewswire/ --...